To provide a detailed overview of thalidomide use in pediatric patients.
DATA SOURCES:
English-language articles were identified through a MEDLINE search (1966–February 2001); key terms included thalidomide, child, graft-versus-host disease, cancer, HIV, Crohn's disease, Behcet's disease, and lupus erythematosus. References cited in those articles were also evaluated.
DATA SYNTHESIS:
Thalidomide appears to be effective in patients with chronic, not acute, graft-versus-host disease (GVHD) and in healing aphthous ulcers in patients with HIV infection. Limited case reports suggest efficacy of thalidomide in the treatment of cutaneous manifestations of Behçet's disease, Crohn's disease, and lupus in children; however, the recurrence of disease is almost universal on drug discontinuation.
CONCLUSIONS:
Thalidomide should be used as a last resort when all other therapies fail, preferably in male or prepubescent female patients.
D'ArcyPFGriffinJP. Thalidomide revisited. Adverse Drug React Toxicol Rev1994; 13: 65–76.
2.
AnnasGJEliasS. Thalidomide and the Titanic: Reconstructing the technology tragedies of the twentieth century. Am J Public Health1999; 89: 98–101.
3.
CalabreseLFleischerAB. Thalidomide: Current and potential clinical applications. Am J Med2000; 108: 487–95.
4.
HusseinMA. Research on thalidomide in solid tumors, hematologic malignancies, and supportive care. Oncology2000; 14 (11suppl 12):9–15.
5.
MarriottJBMullerGDalgleishAG. Thalidomide as an emerging immunotherapeutic agent. Immunol Today1999; 20: 538–40.
6.
KliengebielTSchlegelPG. GVHD: Overview on pathophysiology, incidence, clinical and biological features. Bone Marrow Transplant1998; 21 (suppl 2):S45–49.
7.
MehtaPKedarAGraham-PoleJSkoda-SmithSWingardJ. Thalidomide in children undergoing bone marrow transplantation: Series at a single institution and review of the literature. Pediatrics1999; 103: 806–10.
8.
RovelliAArrigoCNesiFBalduzziANicoliniBLocasciulliA. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children. Bone Marrow Transplant1998; 21: 577–81.
9.
ColeCHRogersPCJPritchardSPhillipsGChanKW. Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation. Bone Marrow Transplant1994; 14: 937–42.
10.
HeneyDBaileyCCLewisIJ. Thalidomide in the treatment of graft-versus-host disease. Biomed Pharmacother1990; 44: 199–204.
11.
McCarthyDMKanferEJBarrettAJ. Thalidomide for the therapy of graft-versus-host disease following allogeneic bone marrow transplantation. Biomed Pharmacother1989; 43: 693–7.
12.
RingdenOAschanJWesterbergL. Thalidomide for severe acute graft-versus-host disease (letter). Lancet1988; 2: 568.
13.
BrownePVWeisdorfDJDeForTMillerWJDaviesSMFilipovichA. Response to thalidomide therapy in refractory chronic graft-versus-host disease. Bone Marrow Transplant2000; 26: 865–9.
14.
ParkerPMChaoNNademaneeAO'DonnellMRSchmidtGMSnyderDS. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood1995; 86: 3604–9.
15.
VogelsangGBHessADSantosGW. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med1992; 326: 1055–8.
16.
MoreiraALSampaioEPZmuidzinasAFrindtPSmithKAKaplanG. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha production by enhancing mRNA degradation. J Exp Med1993; 177: 1675–80.
17.
SampaioEPSarnoENGalillyRCohnZAKaplanG. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med1991; 173: 699–703.
18.
YouleMClarbourJFarthingCConnollyMHawkinsDStaughtonR. Treatment of resistant aphthous ulcerations with thalidomide in patients positive for HIV antibody. Br Med J1989; 298: 432.
19.
SolerRAMiglioratiCvan WaesHNadalD. Thalidomide treatment of mucosal ulcerations in HIV infection. Arch Dis Child1996; 74: 64–5.
20.
JacobsonJMGreenspanJSSpritzlerJKetterNFaheyJJacksonJB. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med1997; 336: 1487–93.
21.
CallenJP. Management of antimalarial-refractory cutaneous lupus erythematosus. Lupus1997; 6: 203–8.
22.
Ordi-RosJCortesFCucurullEMauriMBujanSVilardellM. Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy. J Rheumatol2000; 27: 1429–33.
23.
AtraESatoEI. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheumatol1993; 11: 487–93.
24.
DuongDJSpigelTMoxleyRTIIIGaspariA. American experience with low dose thalidomide therapy for severe cutaneous lupus erythematosus. Arch Dermatol1999; 135: 1079–87.
25.
WalchnerMMeurerMPlewigGMesserG. Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus. Int J Dermatol2000; 39: 383–8.
26.
KnopJBonsmannGHappleRLudolphAMatzDRMifsudEJ. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol1983; 108: 461–6.
27.
WeinsteinARMeaglerAP. Thalidomide in Crohn's disease. Lancet1997; 350: 1445–6.
28.
EhrenpreisEDKaneSVCohenLBCohenRDHanauerSB. Thalidomide therapy for patients with refractory Crohn's disease: An open label trial (abstract). Gastroenterology2000; 43: 1326.
29.
HamuryudanVMatCSaipSOzyazganYSivaAYurdakulS. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet's syndrome. Ann Intern Med1998; 128: 443–50.
30.
JorizzoJLSchmalstiegFCSolomonARJr.CavalloTTaylorRSRudloffHB. Thalidomide effects in Behçet's syndrome and pustular vasculitis. Arch Intern Med1986; 146: 878–81.
31.
OdekaEBMillerV. Thalidomide for oral Crohn's disease refractory to conventional medical therapy. J Pediatr Gastroenterol Nutr1997; 25: 250–1.
32.
WeinsteinTASciubbaJJLevineJ. Thalidomide for the treatment of oral aphthous ulcers in Crohn's disease. J Pediatr Gastroenterol Nutr1999; 28: 214–6.
33.
ShekLPCLeeYSLeeBWLehmanTJA. Thalidomide responsiveness in an infant with Behçet's syndrome. Pediatrics1999; 103: 1295–7.
34.
ChaoNJParkerPMNilandJCWongRMDagisALongGD. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs-host disease. Biol Blood Marrow Transplant1996; 2: 86–92.
